{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458270545
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = xi/i
| target = [[CD4]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration = [[intravenous]]
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 174722-30-6
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Keliximab''' is a [[monoclonal antibody]] for the treatment of severe chronic [[asthma]]. It suppresses the [[immune reaction]] by binding to [[white blood cells]] via the protein  [[CD4]].<ref>{{cite journal|pmid=9798587|year=1998|last1=Kon|first1=OM|last2=Sihra|last3=Compton|last4=Leonard|last5=Kay|last6=Barnes|title=Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma|volume=352|issue=9134|pages=1109â€“13|doi=10.1016/S0140-6736(97)12261-9|journal=Lancet|first2=BS|first3=CH|first4=TB|first5=AB|first6=NC}}</ref> The drug is a [[chimeric protein|chimeric]] antibody from ''[[Macaca irus]]'' and ''[[Homo sapiens]]''.<ref>[http://www.who.int/medicinedocs/index/assoc/s14161e/s14161e.pdf WHO Drug Information]</ref>

==References==
{{reflist}}

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}